A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Inclusion Criteria:

1. Adult male and female patients, at least 18 years-of-age at the time of signature ofthe informed consent form (ICF).

2. Patients with histologically confirmed relapsed/refractory Chronic LymphocyticLeukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL),Follicular Lymphoma (FL), non-GCB Diffuse Large B-cell Lymphoma (DLBCL), MarginalZone Lymphoma (MZL), or Waldenström Macroglobulinemia (WM).

3. Must have received at least 2 prior systemic therapies or have no other therapies toprovide significant clinical benefit in the opinion of the Investigator or who arenot amenable (intolerability, patient choice) to standard therapies.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from study entry:

1. Treatment with any of the following:

• Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever islonger, not to exceed 14 days).

• Systemic chemotherapy within 14 days.

• Radiation therapy within 14 days

• Biologics (Antibodies) treatment within 28 days,

• Radioimmunoconjugates or toxin conjugates within 12 weeks.

• Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use ofimmunoglobulin replacement therapy to treat associated adverse events) within 3months. For patients with DLBCL, no prior CAR- T therapy is allowed.

• Autologous or allogenic stem cell transplant within 100 days and must not haveongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD.

2. History of central nervous system lymphoma/leukemia in remission for less than 2years.

3. Medical history of active bleeding within 2 months prior to study entry, orsusceptible to bleeding by the judgement of investigator.